A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.

Status:
Recruiting

Trial end date:
2023-03-22

Target enrollment:

Participant gender:

Study of safety and efficacy of UNR844 in subjects with presbyopia.

Phase 2

Novartis Pharmaceuticals